Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | WEE1 | P30291 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291480 | 0.83 | PIM1 (0.44) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL20037520 | 0.83 | PIM1 (0.41) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL20249425 | 0.78 | PIM1 (0.39) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL255556 | 0.77 | SLC6A2 (0.43) | PIM1PRMT5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5767440 | 0.76 | PIM1 (0.44) | PIM1PRMT5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20255219 | 0.75 | PRMT5 (0.39) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL29516737 | 0.74 | PIM1 (0.42) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL1578400 | 0.74 | BPTF (0.43) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL18740364 | 0.74 | PIM1 (0.42) | PIM1PRMT5TLR8TLR7SLC6A2 | |
| SCHEMBL13998021 | 0.73 | PLD1 (0.46) | SLC6A4HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PIM1 596/4885PRMT5 1897/4885TLR8 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.